Clarkston Capital Partners LLC acquired a new stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 85,647 shares of the medical instruments supplier's stock, valued at approximately $19,431,000.
Other hedge funds have also recently bought and sold shares of the company. Wesbanco Bank Inc. lifted its position in shares of Becton, Dickinson and Company by 1.9% in the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier's stock worth $580,000 after buying an additional 48 shares during the last quarter. S.A. Mason LLC lifted its holdings in shares of Becton, Dickinson and Company by 3.7% in the 4th quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier's stock worth $321,000 after purchasing an additional 50 shares during the last quarter. Hillsdale Investment Management Inc. boosted its position in Becton, Dickinson and Company by 1.7% during the 4th quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier's stock valued at $694,000 after purchasing an additional 50 shares during the period. Americana Partners LLC boosted its position in Becton, Dickinson and Company by 3.5% during the 4th quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier's stock valued at $345,000 after purchasing an additional 52 shares during the period. Finally, Picton Mahoney Asset Management grew its stake in Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after buying an additional 54 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.
Insider Transactions at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP Richard Byrd sold 1,940 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $224.91, for a total transaction of $436,325.40. Following the transaction, the executive vice president now directly owns 7,411 shares of the company's stock, valued at $1,666,808.01. This represents a 20.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael David Garrison sold 479 shares of the business's stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total value of $94,497.12. Following the completion of the sale, the executive vice president now directly owns 4,887 shares of the company's stock, valued at $964,107.36. This represents a 8.93 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 4,675 shares of company stock valued at $1,057,182. 0.36% of the stock is owned by insiders.
Becton, Dickinson and Company Price Performance
Shares of NYSE BDX traded up $2.18 during mid-day trading on Friday, reaching $201.30. The company had a trading volume of 687,300 shares, compared to its average volume of 1,678,593. The company has a 50-day moving average price of $224.78 and a two-hundred day moving average price of $230.09. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The stock has a market cap of $57.80 billion, a PE ratio of 33.42, a P/E/G ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 1-year low of $193.03 and a 1-year high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company announced that its Board of Directors has initiated a share repurchase program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company's leadership believes its shares are undervalued.
Becton, Dickinson and Company Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Monday, March 10th were issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.07%. The ex-dividend date of this dividend was Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio is currently 69.10%.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the company. Piper Sandler raised their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an "overweight" rating in a research note on Tuesday, January 28th. StockNews.com raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, April 2nd. Finally, Barclays dropped their price target on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating on the stock in a research note on Monday. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $275.71.
Check Out Our Latest Stock Analysis on BDX
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Read More
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
